Real‐world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high‐risk donor seropositive/recipient seronegative (D+R‐) liver transplant recipients (LTxR)
Transplant Infectious Disease · 2023
DOI: 10.1111/tid.14015 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Kathleen M Doss und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Cytomegalovirus Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health,, National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
Abstract (Originalsprache)
Background
Despite superiority of preemptive therapy (PET) compared to universal prophylaxis for prevention of cytomegalovirus (CMV) disease in the CAPSIL randomized trial among CMV D+R‐ liver transplant recipients (LTxRs), real‐world effectiveness may be lower because of logistical concerns about feasibility of PET.
Methods
We retrospectively assessed PET as standard clinical care at a single transplant center among 50 consecutive adult CMV D+R‐ LTxRs undergoing a first liver transplant between 4/4/2019 and 5/18/2021 and compared outcomes and adherence to those randomized to PET in the CAPSIL study ( N = 100). The primary outcome was CMV disease and secondary outcomes were biopsy‐confirmed acute allograft rejection, retransplant, invasive fungal infections, and death, all assessed by 1‐year post‐transplant. Exploratory outcomes included virologic parameters and measures of adherence to protocol‐specified CMV qPCR monitoring.
Results
Baseline characteristics were similar between groups. The cumulative incidence of CMV disease at 1‐year post‐transplant was 4/50 (8%) versus 9/100 (9%) in the real‐world and CAPSIL cohorts, respectively, p = 1.0. The rate of breakthrough CMV disease during the 100‐day PET period was low (2/50 [4%]) and similar to the PET cohort from the CAPSIL study (3/100 [3%]). All secondary and exploratory outcomes were not significantly different between the real‐world and CAPSIL PET cohorts.
Conclusions
In this first reported study of real‐world PET, the feasibility and effectiveness for CMV disease prevention and for other clinical outcomes in CMV D+R‐ LTxRs were similar to those reported with PET in a clinical trial. Additional studies to confirm feasibility and generalizability in other settings are warranted. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
- Division of Transplant Surgery, Department of Surgery, University of Washington, Seattle, Washington, USA.
- Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.
- University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Kathleen M Doss
Förderung
- National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health,
- National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health
Zitieren
APA
Doss, K. M., Kling, C. E., Heldman, M. R., Singh, N., Wagener, M., Rakita, R. M., Fisher, C. E., & Limaye, A. P. (2023). Real‐world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high‐risk donor seropositive/recipient seronegative (D+R‐) liver transplant recipients (LTxR). Transplant Infectious Disease. https://doi.org/10.1111/tid.14015
Vancouver
Doss KM, Kling CE, Heldman MR, Singh N, Wagener M, Rakita RM, et al. Real‐world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high‐risk donor seropositive/recipient seronegative (D+R‐) liver transplant recipients (LTxR). Transplant Infectious Disease. 2023. doi:10.1111/tid.14015
BibTeX
@article{Doss2023,
author = {Doss, Kathleen M and Kling, Catherine E and Heldman, Madeleine R and Singh, Nina and Wagener, Marilyn and Rakita, Robert M and Fisher, Cynthia E and Limaye, Ajit P},
title = {Real‐world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high‐risk donor seropositive/recipient seronegative (D+R‐) liver transplant recipients (LTxR)},
journal = {Transplant Infectious Disease},
year = {2023},
doi = {10.1111/tid.14015}
}
EUVIMED